J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

Johnson & Johnson's investigational oral peptide drug icotrokinra (JNJ-2113) demonstrated superior efficacy over Bristol Myers Squibb's Sotyktu (deucravacitinib) in late-stage (Phase 3) plaque psoriasis trials23.

Icotrokinra, a first-in-class targeted oral IL-23 receptor antagonist, achieved higher rates of skin clearance and symptom improvement compared to both Sotyktu and placebo, setting a new standard for oral psoriasis therapies23.

In Phase 3 ICONIC-ADVANCE 1 & 2 studies, icotrokinra outperformed deucravacitinib at Weeks 16 and 24 for skin clearance, with similar adverse event rates to placebo37.

ICONIC-LEAD study showed that 65% of icotrokinra-treated patients reached clear or almost clear skin at Week 16, versus just 8% for placebo, and 50% achieved a 90% improvement in symptom severity2.

Long-term results at Week 52 indicated sustained skin clearance for both adults and adolescents, with a favorable safety profile and no major new safety concerns identified34.

Icotrokinra also demonstrated significant efficacy in difficult-to-treat scalp and genital psoriasis, with 66% and 77% of patients, respectively, achieving clear or almost clear skin at Week 165.

The promising results position icotrokinra as a potential new oral treatment of choice for moderate to severe plaque psoriasis, especially for patients seeking alternatives to injectable biologics123.

Sources:

1. https://trial.medpath.com/news/651bfa752ce2b462/j-j-s-new-psoriasis-drug-shows-breakthrough-results-in-phase-3-trial-74-success-rate

2. https://www.biospace.com/drug-development/j-js-oral-il-23r-blocker-sets-new-standard-in-plaque-psoriasis-beating-bmss-sotyktu

3. https://www.prnewswire.com/news-releases/icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-reinforcing-promise-of-novel-targeted-oral-peptide-for-treatment-of-plaque-psoriasis-302557781.html

4. https://www.dermatologytimes.com/view/johnson-johnson-seeks-ema-approval-for-oral-il-23-antagonist-icotrokinra

5. https://www.jnj.com/media-center/press-releases/icotrokinra-results-show-significant-skin-clearance-in-patients-with-difficult-to-treat-scalp-and-genital-psoriasis

7. https://www.jnj.com/media-center/press-releases/icotrokinra-shows-superiority-to-deucravacitinib-in-first-reported-head-to-head-trials-reinforcing-promise-of-novel-targeted-oral-peptide-for-treatment-of-plaque-psoriasis